ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency
about
Copine-III interacts with ErbB2 and promotes tumor cell migrationp27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistanceAltered p27(Kip1) phosphorylation, localization, and function in human epithelial cells resistant to transforming growth factor beta-mediated G(1) arrestInhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cellsA collection of breast cancer cell lines for the study of functionally distinct cancer subtypesp27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapyThe ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferationThe cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer.Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancerTyrosine kinase signalling in breast cancerDeregulation of p27 by oncogenic signaling and its prognostic significance in breast cancerCharacterization of a prostate-specific tyrosine phosphatase by mutagenesis and expression in human prostate cancer cellsGenes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signalingThe ErbB signaling network: receptor heterodimerization in development and cancerModeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistanceAnti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations.A COX-2 inhibitor nimesulide analog selectively induces apoptosis in Her2 overexpressing breast cancer cells via cytochrome c dependent mechanisms.Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells.Targeting HER2 in breast cancer: overview of long-term experienceErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cellsp27: a barometer of signaling deregulation and potential predictor of response to targeted therapies.Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis.Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.Hunk is required for HER2/neu-induced mammary tumorigenesis.Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growthTargeted inhibition of kinases in cancer therapyTargeting the function of the HER2 oncogene in human cancer therapeutics.WISP-2 gene in human breast cancer: estrogen and progesterone inducible expression and regulation of tumor cell proliferation.MYC and Breast Cancer.The role of the cyclin D1-dependent kinases in ErbB2-mediated breast cancerEngineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes.Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.An unexpected role for caspase-2 in neuroblastoma.Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast CancerER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamideRole of HER receptors family in development and differentiation.Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implicationsInteraction of a standardized mistletoe (Viscum album) preparation with antitumor effects of Trastuzumab in vitro.Reinforcing targeted therapeutics with phenotypic stability factors
P2860
Q22001536-150CBDDF-2F5E-4623-8F00-E65DFE8ED077Q24294568-1B80E0D7-FD97-4779-8F13-AB4B7EBD4631Q24309891-B95BB963-5E85-4FE2-B85C-4571215E2DE3Q24537257-375F64C1-E1CC-4F3B-95CA-C367B671C796Q24561962-1CAC557F-6600-4E71-9B89-495DBA4F8F12Q24647928-0C54ADA4-84AD-4666-B3B0-68978795A971Q24650994-67D5EB16-8953-48A2-8E64-DE3989BD56DAQ24678674-D5022F87-5613-4278-815A-766D969F22E8Q24793380-19A6E6D5-A0DA-48E8-A417-DCBC71B678C2Q24795614-7BCA08F8-4DB6-4723-83E1-810DF70F817DQ24802908-CCF73324-1E82-47A0-9F16-6B39BC6AAFB0Q24803723-4AC11FCE-78D1-4F3A-9942-5568FE519B79Q28118863-294735AA-0027-43B3-A00F-4DE7934B8CF5Q28289659-548F262E-1A52-4E18-8630-FDD3E0556351Q29617919-DCF114B9-7EDD-4185-98E0-A15473FD3DC3Q33396832-3146A81A-3A58-4AE5-BF84-96B6C7FCC32FQ34173557-234C86C7-04F2-48FE-B75E-FFDCD2099739Q34197523-544CE48F-1640-4F6A-A435-ABC4762F7B0FQ34227971-4800F09A-85FD-4A89-918C-FCE7F3114848Q34272044-BCED11F9-EB3E-4776-B1C7-7C9ADDC2C34DQ34276145-0CA3ECD0-E069-4AB2-9498-38CE92097122Q34472383-BD317F02-7B1A-45C6-9B6D-8B3964C24BA4Q34607187-A3D56B1B-D479-4417-9E0C-05BDF961F408Q34621219-EF68C722-9A61-409B-B42B-9C9A480599EEQ34627179-54060FBD-9726-461C-A898-C3576BF3F7EFQ34669979-8C2AEF70-940A-4685-973C-708F80F2B2E2Q34683348-6255AD14-1AA4-4329-926A-0AF2319B4C2EQ34766486-9F2DA3E3-0076-4302-B9DB-BF13F796501AQ34770234-4F8F81D7-CCD1-4521-BFE1-53B0716F9C4DQ34972381-148EA25D-1BF3-4E95-B6A6-93227191A4BFQ35096122-D143A42D-3C0A-4020-B3AE-C9CCE6455E6FQ35145024-7DB360E3-7D55-43B2-9542-9DC93004B684Q35624814-6BBC7D27-3B3C-451C-9A40-2353E334A7BEQ35679550-7AB94BCE-B86F-4A7C-A459-F70EBE9D5F14Q35684440-966B283C-8CEE-4564-B5AA-AEBFEB30BE12Q35765844-4CD6A95F-A81D-423C-B8C3-2EA513B502A6Q35837065-9BF03C3C-AA3E-4577-92EE-F671D060C13AQ36088788-A8F01239-999F-44F0-92AB-200C026930DBQ36095351-F140BCAA-C567-4E33-B99F-2CB09CFE8EE0Q36187514-7855F703-5789-483F-9923-D29DDFE2139E
P2860
ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
ErbB2 potentiates breast tumor ...... ot determine growth dependency
@ast
ErbB2 potentiates breast tumor ...... ot determine growth dependency
@en
type
label
ErbB2 potentiates breast tumor ...... ot determine growth dependency
@ast
ErbB2 potentiates breast tumor ...... ot determine growth dependency
@en
prefLabel
ErbB2 potentiates breast tumor ...... ot determine growth dependency
@ast
ErbB2 potentiates breast tumor ...... ot determine growth dependency
@en
P2093
P2860
P1476
ErbB2 potentiates breast tumor ...... ot determine growth dependency
@en
P2093
P2860
P304
P356
10.1128/MCB.20.9.3210-3223.2000
P407
P577
2000-05-01T00:00:00Z